Coccidioidomycosis cost-effectiveness of therapy

Revision as of 01:19, 21 September 2017 by Mmir (talk | contribs) (Category)
Jump to navigation Jump to search

Coccidioidomycosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Coccidioides immitis
Coccidioides posadasii

Differentiating Coccidioidomycosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

MRI

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Coccidioidomycosis cost-effectiveness of therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Coccidioidomycosis cost-effectiveness of therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Coccidioidomycosis cost-effectiveness of therapy

CDC on Coccidioidomycosis cost-effectiveness of therapy

Coccidioidomycosis cost-effectiveness of therapy in the news

Blogs on Coccidioidomycosis cost-effectiveness of therapy

Directions to Hospitals Treating Coccidioidomycosis

Risk calculators and risk factors for Coccidioidomycosis cost-effectiveness of therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]:Associate Editor(s)-in-Chief: Aditya Ganti M.B.B.S. [2]

Overview

Given the morbidity and mortality associated with coccidioidomycosis infection, and the low cost of safe and effective antifungals, current pharmacotherapy to treat coccidioidomycosis is relatively cost-effective.[1]

References

  1. Stockamp NW, Thompson GR (2016). "Coccidioidomycosis". Infect. Dis. Clin. North Am. 30 (1): 229–46. doi:10.1016/j.idc.2015.10.008. PMID 26739609.

Template:WH Template:WS